AU7788500A - Use of substance p antagonists for influencing the circadian timing system - Google Patents

Use of substance p antagonists for influencing the circadian timing system

Info

Publication number
AU7788500A
AU7788500A AU77885/00A AU7788500A AU7788500A AU 7788500 A AU7788500 A AU 7788500A AU 77885/00 A AU77885/00 A AU 77885/00A AU 7788500 A AU7788500 A AU 7788500A AU 7788500 A AU7788500 A AU 7788500A
Authority
AU
Australia
Prior art keywords
antagonists
influencing
substance
timing system
circadian timing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77885/00A
Inventor
Christine Jeanne Dugovic
Frans Eduard Janssens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU7788500A publication Critical patent/AU7788500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
AU77885/00A 1999-10-25 2000-10-16 Use of substance p antagonists for influencing the circadian timing system Abandoned AU7788500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99203499 1999-10-25
EP99203499 1999-10-25
PCT/EP2000/010201 WO2001030348A1 (en) 1999-10-25 2000-10-16 Use of substance p antagonists for influencing the circadian timing system

Publications (1)

Publication Number Publication Date
AU7788500A true AU7788500A (en) 2001-05-08

Family

ID=8240775

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77885/00A Abandoned AU7788500A (en) 1999-10-25 2000-10-16 Use of substance p antagonists for influencing the circadian timing system

Country Status (3)

Country Link
AR (1) AR026225A1 (en)
AU (1) AU7788500A (en)
WO (1) WO2001030348A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AR036366A1 (en) 2001-08-29 2004-09-01 Schering Corp USEFUL PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A KIT
EP1515722A4 (en) 2002-06-17 2006-06-21 Merck & Co Inc Ophthalmic compositions for treating ocular hypertension
ATE400568T1 (en) 2002-12-23 2008-07-15 Janssen Pharmaceutica Nv SUBSTITUTED 4-(4-PIPERIDINE-YL-PIPERAZINE-1-YL)-AZEPAN DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في Substituted 1- Piperidin- 3- Yl- 4- Piperidin- 4- Yl- Piperazine Derivatives and their Use as Neurokinin Antagonists
US7435736B2 (en) 2002-12-23 2008-10-14 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
KR20060006098A (en) 2003-06-10 2006-01-18 얀센 파마슈티카 엔.브이. Substituted 1,4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments
ES2350647T3 (en) 2005-03-08 2011-01-25 Janssen Pharmaceutica Nv DERIVATIVES OF DIAZA-ESPIRO- [4.4] -NONANO AS AN ANTHOGONIST OF NEUROQUININS (NK1).
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
GB0808030D0 (en) 2008-05-01 2008-06-11 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
AU3716997A (en) * 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
AU723414B2 (en) * 1996-09-25 2000-08-24 Merck Sharp & Dohme Limited Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists

Also Published As

Publication number Publication date
AR026225A1 (en) 2003-01-29
WO2001030348A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
AU2002212226A1 (en) Use of indole derivatives for treating illnesses of the central nervous system
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
AU2177001A (en) Use of indirubine derivatives for making medicines
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
AU4364400A (en) Azaindole derivatives for the treatment of depression
AU4213299A (en) Controlled release of substances
ZA200201521B (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
AU5820900A (en) Capsule for the controlled release of active substances
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
IL148640A0 (en) Processes for the preparation of sumatriptan and related compounds
PL351088A1 (en) Process for the preparation of substituted pyrimidines
AUPQ232599A0 (en) Drug for treating fractures
ZA981885B (en) Method for the preparation of alpha-bromo-lactam derivatives
AU7080798A (en) Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
AU2829700A (en) Processes for the preparation of alpha-aminoketones
AU4151700A (en) Process for the preparation of caprolactam
HUP0001558A3 (en) Process for the preparation of pirlindole hydrochloride
AU1130901A (en) Method for the preparation of 5-carboxyphthalide
ZA98484B (en) Use of beta3-adrenergic receptor agonists for the preparation of healing drugs
AU6028900A (en) Method for the preparation of urea
AU5315000A (en) Indicators for monitoring the technique of transcutaneous immunization

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase